|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Nociceptive Pain - Safety Profile Uppermost in Crowded Market
Datamonitor, Oct 2004, Pages: 264
CHAPTER 1 EXECUTIVE SUMMARY
Scope of the analysis
Our insight into the nociceptive pain market
There are few novel drugs in the nociceptive pain pipeline, and market specialization is currently the most popular drug development strategy.
Morphine is still the most effective treatment available for nociceptive pain, and nothing in the pipeline looks set to replace it for the foreseeable future.
In-depth trial data on the safety of new NSAID drugs is key to their success in a market where it may be the only factor with which to differentiate between drugs. After Vioxx's withdrawal, longer and more detailed trials will be needed.
Many of the pipeline drugs for nociceptive pain are reformulations of previously marketed drugs, or drug types. It is doubtful this strategy will bring much success when experts prefer standard oral tablets, and it is a trend that cannot continue for much longer
Summary
Key metrics
Our pipeline assessment summary
CHAPTER 2 PATIENT POTENTIAL
Definition of pain
Nociceptive pain
Neuropathic pain
Segmentation and epidemiology of nociceptive pain
Acute pain
Postoperative pain
Cancer pain
Breakthrough pain
Chronic non-malignant pain
Arthritis
HIV-related pain
Back pain
Diagnosis of pain type
Diagnosis of pain severity
Treatment of nociceptive pain
Acute pain and cancer pain
Chronic non-malignant pain
Unmet needs in nociceptive pain
Improved efficacy
Adverse side effects
Opioids
NSAIDS
Around-the-clock pain management
Physician awareness
Patient awareness
CHAPTER 3 R&D APPROACH
Classification of pipeline products
Opioids
Opioid combination therapies
NSAIDs
Other analgesics
Adjuvant analgesics
Clinical trial design in nociceptive pain
Design
Patient population
Duration
Gold standard
Clinical trial endpoints in nociceptive pain
Pain questionnaires
Other endpoints
Dose-response relationships
Pain diaries
Demand for opiates
CHAPTER 4 NOCICEPTIVE PAIN PIPELINE ANALYSIS
Pipeline overview
Key companies involved in the nociceptive pain pipeline
GSK
Merck & Co.
Endo
Strategies for success
Pain prevention
Drug delivery formulations/reformulations
Oral delivery formulations
Intravenous delivery formulations
Transmucosal delivery formulations
Transdermal delivery formulations
Key drug delivery strategies in the pain market
Depression and pain relief
CHAPTER 5 OPIOID DRUGS LATE-STAGE DRUG ANALYSIS & FORECASTS
Overview for opioid drugs
Pipeline summary
Opioid summary
Definition of current comparator therapy
DepoDur
Drug overview
Clinical trial data
Phase III
Phase II
Phase III
Patient potential
Marketing
Satisfaction of unmet needs
Forecasts to 2014
Drug assessment summary
Contramid tramadol
Drug overview
Clinical trial data
Phase III
Phase II
Patient potential
Marketing
Satisfaction of unmet needs
Forecasts to 2014
Drug assessment summary
E-TRANS fentanyl (Ionsys)
Drug overview
Clinical trial data
Phase III
Phase II
Phase I
Patient potential
Marketing
Satisfaction of unmet needs
Forecasts to 2014
Drug assessment summary
CEE-04-410
Drug Overview
Clinical trial data
Phase III
Phase II
Patient potential
Marketing
Satisfaction of unmet needs
Forecasting to 2014
Drug assessment summary
Other opioids
Cancer pain
M6G
Morphine (nasal formulation)
Clinical trial data
OxyTrex (PTI-801)
Clinical trial data
Rapinyl
TA-2620
Chronic non-malignant pain
Chronogesic
Clinical trial data
CJC-1008
Clinical trial data
Dilaudid (hydromorphone) CR
JTC-801
Oxymorphone IR & ER
Clinical trial data
Q-8003
Ralivia ER
Tramadol hydrochloride controlled-release (THCR)
VANH-36
Acute pain
Aero-LEF
DPI-3290 (ORG-41793)
REN-213 / REN-214
Late-stage development compounds recently discontinued
MorphiDex
Oral transmucosal fentanyl
Morphine Medipad
Comparison of key compounds in opioid drugs
Improved efficacy
Better side-effect profile
Around-the-clock pain management
Physician/patient awareness
Marketing strength
Comparative forecasts
CHAPTER 6 NSAIDS LATE-STAGE DRUG ANALYSIS AND FORECASTS
Overview for NSAIDs
Pipeline summary
Definition of current comparator therapy
COX-2 inhibitors
Prexige (lumiracoxib) 166
Drug overview
Clinical trial data
Patient potential
Marketing
Satisfaction of unmet needs
Forecasts to 2014
Drug assessment summary
Licofelone
Drug overview
Clinical trial data
Patient potential
Marketing
Satisfaction of unmet needs
Forecasts to 2014
Drug assessment summary
Other COX-2 inhibitors
Cimicoxib
Clinical trial data
GW-406381
Standard NSAIDs
NO-naproxen (HCT 3012)
Phase II
Phase I
Marketing
Lipoxin-A
Acetaminophen
Intravenous diclofenac
Late-stage development compounds recently discontinued
NO-COX-2 inhibitor
Comparison of key compounds in NSAIDs
Improved efficacy
Better side-effect profile
Around-the-clock pain management
Physician/patient awareness
Marketing strength
Comparative forecasts
CHAPTER 7 OTHER ANALGESICS LATE-STAGE DRUG ANALYSIS AND FORECASTS
Overview for other analgesics
Pipeline summary
Definition of current comparator therapy
Cannabinoids
THC monotherapy
Drug overview
Clinical trial data
Patient potential
Marketing
Satisfaction of unmet needs
Forecasting to 2014
Drug assessment summary
SAB-378
Other analgesics
Prialt (ziconotide)
Drug overview
Clinical trial data
Patient potential
Marketing
Satisfaction of unmet needs
Forecasts to 2014
Drug assessment summary
Bicifadine SR
Drug overview
Clinical trial data
Patient potential
Marketing
Satisfaction of unmet needs
Forecasting to 2014
Drug Assessment
ALGRX 4975
Tectin
Clinical trial data
Intranasal ketamine
Clinical trial data
LidoPAIN-SP / BP
Clinical trial data
EpiCept MS Spray
LY-293558
Clinical trial data
APF-112
Clinical trial data
Anti-inflammatory drugs
M-40403
NCX-701
Clinical trial data
AM-336
Late-stage development compounds recently discontinued
Fadolmidine
Tebanicline
YM-598
Comparison of key compounds in other analgesics
Improved efficacy
Better side-effect profile
Around-the-clock pain management
Physician/patient awareness
Marketing strength
Comparative forecasts
CHAPTER 8 INNOVATIVE EARLY-STAGE PROJECTS
Key Phase I and preclinical compounds in nociceptive pain
Acetylcholine receptor modulators
Bradykinin antagonists
Vanilloid receptor antagonists
Key research impacts on nociceptive pain
Gene therapy for pain
APPENDIX A
Contributing experts
Bibliography
General
Epidemiology
Clinical trial data
Websites
Report methodology
Pipeline-drug forecast methodology
Predicting initial market share
Clinical competitiveness attributes
Order of entry
Pre-launch awareness
Market composition
Marketing plan
Marketing strength
Forecasting future growth
Influencing factors
Drug assessment summary
APPENDIX B
Our Healthcare
Our Healthcare research and analysis methodologies
Our Healthcare therapy area capabilities
About the CNS analysis team
Key therapy team members
Lynda Lynch, Director CNS
David Abramson, Therapeutic Lead Consultant
Disclaimer
Customers who bought this item also bought
Pain Therapeutics - Drugs, Markets and Companies
US Cancer Pain Report
Back Pain Report 2008
Drugs of Tommorrow 2002: Pain
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
The Pain Management Market Outlook To 2014: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Commercial Insight: Pain Market Overview - Non-traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
Pain Management - Global Strategic Business Report
The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape
The Pain Market Outlook to 2011
The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape
|
|
|
|
